Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02560025
Title Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

acute myeloid leukemia

Therapies

Alisertib

Daunorubicin

Idarubicin

Cytarabine

Age Groups: adult
Covered Countries USA


No variant requirements are available.